Renal anemia is a common complication of chronic kidney disease (CKD). Although there are treatments for the disease, physicians, patients, and healthcare systems have concerns about their limitations. Delivery, safety issues, and tightening healthcare budgets have resulted in increased scrutiny of the effectiveness and tolerability of such therapies as intravenous (IV) iron and erythropoiesis-stimulating agents (ESAs). The renal anemia therapy market will expand over the 2019-2029 study period, fueled by increasing prevalence and demand for new drugs that can effectively, safely, and conveniently control the disease. The launches of several hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors are expected during the study period. Although these new therapies offer advantages over current therapies, they will face major challenges, including reimbursement hurdles and an increasingly stringent regulatory environment.
QUESTIONS ANSWERED
What opportunities exist for the marketers of the emerging oral HIF-PH inhibitors to promote their noninvasive route of administration, particularly for patients not on dialysis?
Will establishing cardiovascular (CV) safety be key for the market uptake of HIF-PH inhibitors given the CV issues associated with current therapies?
With the availability of biosimilars in the United States, will emerging therapies offering only incremental improvements over existing therapies struggle?
CONTENT HIGHLIGHTS
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 20 country-specific interviews with thought-leading nephrologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Prevalence of renal anemia by country and diagnosed/ drug-treated rates.
Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
Market forecast features: 10-year, annualized, drug-level sales and patient share of key renal anemia therapies through 2029, segmented by brands / generics.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Factors Influencing Drug Selection in Renal Anemia
Region-Specific Treatment Practices
Treatment Decision Tree for Renal Anemia: United States
Treatment Decision Tree for Renal Anemia: Europe
Treatment Decision Tree for Renal Anemia: Japan
Unmet Need Overview
Current and Future Attainment of Unmet Needs in Renal Anemia
Top Unmet Needs in Renal Anemia: Current and Future Attainment
Emerging Therapies
Key Findings
Key Emerging Therapies
Key Therapies in Development for Renal Anemia
Estimated Launch Dates of Key Emerging Therapies for the Treatment of Renal Anemia
Roxadustat Profile
Analysis of the Clinical Development Program for Roxadustat
Expert Insight: Roxadustat
Expectations for Launch and Sales Opportunity of Roxadustat in Renal Anemia
Vadadustat Profile
Analysis of the Clinical Development Program for Vadadustat
Expert Insight: Vadadustat
Expectations for Launch and Sales Opportunity of Vadadustat in Renal Anemia
Daprodustat Profile
Analysis of the Clinical Development Program for Daprodustat
Expert Insight: Daprodustat
Expectations for Launch and Sales Opportunity of Daprodustat in Renal Anemia
Molidustat Profile
Analysis of the Clinical Development Program for Molidustat
Expert Insight: Molidustat
Expectations for Launch and Sales Opportunity of Molidustat in Renal Anemia
Enarodustat Profile
Analysis of the Clinical Development Program for Enarodustat
Expert Insight: Enarodustat
Expectations for Launch and Sales Opportunity of Enarodustat in Renal Anemia
Early-Phase Pipeline Analysis
Select Phase I and Preclinical Development Programs for Renal Anemia
Access & Reimbursement Overview
Region-Specific Reimbursement Practices
Key Market Access Considerations in Renal Anemia: United States
General Reimbursement Environment: United States
Key Market Access Considerations in Renal Anemia: EU5
General Reimbursement Environment: EU5
Key Market Access Considerations in Renal Anemia: Japan
General Reimbursement Environment: Japan
Appendix
Renal Anemia Bibliography
Tej Pal, M.Pharm.
Tej Pal, M.Pharm., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Diseases team at Clarivate. Previously, he was an analyst at IQVIA and at Smart Analyst Inc., where he worked closely with top pharmaceutical companies on commercial and technical ad-hoc requests. During his tenure there, he delivered competitive landscape and market insight projects on various oncology indications. He holds a master’s degree in pharmacy with a specialization in pharmaceutical chemistry from the Delhi Institute of Pharmaceutical Sciences and Research in New Delhi, India.